Ozempic-Style Drugs May Slow Biological Aging, Not Just Shrink Waistlines
- Design
- Journal Article
- Participants
- N/A
- Duration
- —
- Funding
- —
This review suggests GLP-1 drugs may affect aging biology beyond weight loss, but confirmation trials are pending.
GLP-1 drugs like semaglutide cut deaths and heart problems by more than their weight and blood sugar effects alone would explain. This review pulls together the evidence, including a 2025 trial where 32 weeks of semaglutide slowed three well-known epigenetic clocks (blood tests that estimate how fast you're aging). Researchers think pathways like AMPK and SIRT1, plus gut bacteria changes, may be involved. It's still early, and no trial has been designed specifically to test aging as the main outcome.
Disclaimer: Research summaries are provided for informational purposes only and do not constitute medical advice. Always consult a qualified healthcare professional before making changes to your health routine.
Related Studies
All researchA Hidden Cloak Lets Zombie Cells Dodge Your Immune System
Senescent cells (worn-out cells that stop dividing but refuse to die) pile up with age and drag down metabolism and muscle.
Why Muscle Quality Matters So Much on GLP-1 Weight Loss Drugs
Drugs like Ozempic drop weight fast, but some of that loss is muscle, not just fat.
Semaglutide Slowed a Blood-Based Dementia Risk Score in Older Heart Patients
Older adults with excess weight and heart disease but no diabetes took semaglutide or a placebo for two years.